Portfolio Sync Solutions
Streamline your investment strategy with our portfolio synchronization tools. Seamlessly manage and track your holdings across platforms for enhanced
GET STARTEDNektar Therapeutics Analyst EPS Estimates
| Quarter | Number of Estimates | Low Estimate | High Estimate | Average Estimate |
|---|---|---|---|---|
| Q1 2025 | 4 | -$0.22 | -$0.16 | -$0.19 |
| Q2 2025 | 2 | -$0.28 | -$0.12 | -$0.19 |
| Q3 2025 | 2 | -$0.29 | -$0.12 | -$0.20 |
| Q4 2025 | 2 | -$0.30 | -$0.12 | -$0.20 |
| Q1 2026 | 1 | -$0.32 | -$0.13 | -$0.22 |
| Q2 2026 | 1 | -$0.34 | -$0.14 | -$0.23 |
| Q3 2026 | 1 | -$0.34 | -$0.14 | -$0.23 |
| Q4 2026 | 1 | -$0.34 | -$0.14 | -$0.23 |
| Q1 2027 | 1 | -$0.33 | -$0.14 | -$0.22 |
| Q2 2027 | 1 | -$0.33 | -$0.13 | -$0.22 |
| Q3 2027 | 1 | -$0.32 | -$0.13 | -$0.22 |
| Q4 2027 | 1 | -$0.32 | -$0.13 | -$0.22 |
Nektar Therapeutics Earnings Date And Information
Nektar Therapeutics last posted its earnings results on Wednesday, March 12th, 2025. The company reported $-0.15 earnings per share for the quarter, missing analysts' consensus estimates of $-0.13 by $0.02. The company had revenue of 24.12 M for the quarter and had revenue of 90.12 M for the year. Nektar Therapeutics has generated $-1 earnings per share over the last year ($-1.45 diluted earnings per share) and currently has a price-to-earnings ratio of -1.01. Nektar Therapeutics has not formally confirmed its next earnings publication date, but the company's estimated earnings date is Monday, March 3rd, 2025 based on prior year's report dates.
Nektar Therapeutics Earnings History by Quarter
| Date | Quarter | Consensus Estimate | Reported EPS | Beat/Miss | Revenue Estimate | Actual Revenue |
|---|---|---|---|---|---|---|
| 11/07/2024 | Q3 2024 | N/A | -$0.18 | N/A | $19.18 M | $24.12 M |
| 08/08/2024 | Q2 2024 | N/A | -$0.25 | N/A | $18.20 M | $23.49 M |
| 05/09/2024 | Q1 2024 | N/A | -$0.19 | N/A | N/A | $21.64 M |
| 03/05/2024 | Q4 2023 | N/A | -$0.22 | N/A | N/A | $23.89 M |
| 11/07/2023 | Q3 2023 | N/A | -$0.24 | N/A | $21.26 M | $24.14 M |
| 08/08/2023 | Q2 2023 | N/A | -$0.27 | N/A | $21.79 M | $20.50 M |
| 05/09/2023 | Q1 2023 | N/A | -$0.73 | N/A | N/A | $21.59 M |
| 02/28/2023 | Q4 2022 | -$0.45 | -$0.32 | 0.13 | N/A | $22.02 M |
| 11/04/2022 | Q3 2022 | N/A | -$0.31 | N/A | $22.61 M | $23.63 M |
| 08/04/2022 | Q2 2022 | N/A | -$0.85 | N/A | $22.62 M | $21.59 M |
| 05/05/2022 | Q1 2022 | N/A | -$0.49 | N/A | N/A | $24.82 M |
| 02/28/2022 | Q4 2021 | N/A | -$0.79 | N/A | N/A | $25.01 M |
| 11/04/2021 | Q3 2021 | N/A | -$0.70 | N/A | $28.13 M | $24.92 M |
| 08/05/2021 | Q2 2021 | N/A | -$0.69 | N/A | $26.15 M | $28.33 M |
| 05/06/2021 | Q1 2021 | N/A | -$0.68 | N/A | N/A | $23.65 M |
| 02/25/2021 | Q4 2020 | N/A | -$0.65 | N/A | N/A | $23.46 M |
| 11/05/2020 | Q3 2020 | N/A | -$0.61 | N/A | $22.59 M | $30.03 M |
| 08/06/2020 | Q2 2020 | N/A | -$0.45 | N/A | $22.76 M | $48.85 M |
| 05/07/2020 | Q1 2020 | N/A | -$0.78 | N/A | N/A | $50.57 M |
| 02/27/2020 | Q4 2019 | N/A | -$0.64 | N/A | N/A | $33.86 M |
Explore Related Stocks for Market Trends
Explore our related stocks for the latest market trends and stock news to stay informed and make better decisions.
Nektar Therapeutics Earnings: FAQ's
Nektar Therapeutics has not confirmed its next earnings publication date, but the company's estimated earnings date is Monday, March 3rd, 2025 based offlast year's report dates.
The conference call for Nektar Therapeutics's latest earnings report can be listened to online.
The conference call transcript for Nektar Therapeutics's latest earnings report can be read online.
Nektar Therapeutics (:NKTR) has a recorded annual revenue of $90.12 M.
Nektar Therapeutics (:NKTR) has a recorded net income of $-276,056,000.Nektar Therapeutics has generated $-1.45 earnings per share over the last four quarters.
Nektar Therapeutics (:NKTR) has a price-to-earnings ratio of -1.01 and price/earnings-to-growth ratio is -0.15.